RELATIVITY-047: Extended Analysis Of Overall Survival With Nivolumab/Relatlimab vs Nivolumab In Previously Untreated Advanced Melanoma

Source: The ASCO Post, January 2025

In an extended analysis of the phase II/III RELATIVITY-047 trial reported in the Journal of Oncology, Tawbi et al found a significant overall survival benefit with nivolumab/relatlimab vs nivolumab in previously untreated patients with unresectable advanced stage III or IV melanoma.

The Initial report from the trial showed that nivolumab/relatlimab significantly improved progression-free survival vs nivolumab, with a clinically meaningful but nonsignificant improvement in overall survival and a numerically higher objective response rate.

Study Details

In the global trial, 714 patients were randomly assigned to receive nivolumab at 480 mg and relatlimab at 160 mg as a fixed-dose combination (n = 355) or nivolumab at 480 mg every 4 weeks. The current analysis describes outcomes after a median follow-up of 33.8 months (range = 0.3–64.2 months).
READ THE ORIGINAL
FULL ARTICLE